2024-11-10 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Analysis:**

**1.  Performance vs. S&P 500:**

   * **Cumulative Return:** ABT (105.94%) vs. S&P 500 (VOO) (141.71%).  ABT is trailing the S&P 500 by 35.77%.
   * **Relative Outperformance:**  Currently, ABT's relative outperformance is at the 8.23% percentile based on historical data.  
   * **Alpha & Beta Analysis:**
      * ABT has shown consistent alpha (outperformance compared to the benchmark) over the past years, particularly in 2016-2019.
      * Its beta (volatility compared to the benchmark) has been consistently lower than 1, suggesting lower risk than the S&P 500.

**2.  Recent Price Movement:**

   * **Closing Price:** $115.3 (Last Market: $116.69)
   * **5-Day Moving Average:** $117.22
   * **20-Day Moving Average:** $116.34
   * **60-Day Moving Average:** $114.7

**3.  Technical Indicators:**

   * **RSI:** 39.0 (below 50, suggesting potential oversold conditions)
   * **PPO:** -0.03 (negative value indicates bearish sentiment)
   * **Delta_Previous_Relative_Divergence:** -6.5 (short-term downtrend)
   * **Expected Return:** 0.0% (estimated long-term (2+ years) return relative to the S&P 500)

**4.  Recent Earnings & Outlook:**

   * **Earnings (EPS) & Revenue:**
      | Date      | EPS  | Revenue     |
      |-----------|------|--------------|
      | 2024-10-31 | 0.94 | $10.63 B$  |
      | 2024-07-31 | 0.74 | $10.38 B$  |
      | 2024-05-02 | 0.70 | $9.96 B$   |
      | 2023-11-01 | 0.82 | $10.14 B$  |
      | 2024-10-31 | 0.82 | $10.14 B$  |
   * **Analysis:**  EPS growth has been consistent, with the latest earnings exceeding analysts' expectations. 
   * **Note:**  Include the most recent earnings estimate in your analysis for a complete picture.

**5.  Financial Information:**

   **1) Revenue and Profitability:**

   | Quarter     | Revenue | Profit Margin |
   |------------|---------|--------------|
   | 2024-09-30 | $10.63B | 55.83%       |
   | 2024-06-30 | $10.38B | 55.64%       |
   | 2024-03-31 | $9.96B  | 55.21%       |
   | 2023-12-31 | $10.24B | 55.51%       |
   | 2023-09-30 | $10.14B | 54.60%       |

   **2) Capital and Profitability:**

   | Quarter     | Equity | ROE  |
   |------------|--------|------|
   | 2024-09-30 | $39.80B| 4.14%|
   | 2024-06-30 | $39.32B| 3.31%|
   | 2024-03-31 | $38.81B| 3.16%|
   | 2023-12-31 | $38.60B| 4.13%|
   | 2023-09-30 | $37.48B| 3.83%|

   **Analysis:**  ABT demonstrates strong profitability with consistently high profit margins and healthy equity levels.

**6.  News and Recent Issues:**

   * **Recent Earnings News:** Refer to sources like Shacknews or other financial news platforms for the latest earnings release and market reactions.
   * **Market Outlook:** Analyze recent market sentiment towards ABT using platforms like Finbold. This will include analyst opinions, price targets, and other performance highlights. 

**7.  Overall Analysis:**

   * ABT shows consistent profitability and has historically outperformed the S&P 500. 
   * The recent decline in price and technical indicators suggests a potential oversold condition, but the expected return is negligible. 
   * It's crucial to monitor news and analyst opinions for a comprehensive assessment.

**In conclusion, while ABT has shown strong fundamentals and historical outperformance, its current price trajectory and market sentiment require close monitoring. Investors seeking long-term growth should consider carefully evaluating its recent performance and future prospects before making any investment decisions.** 
